Key result
Intravenous NaEDTA was administered in 14 instances of supraventricular and ventricular arrhythmia to evaluate its utility as a test of digitalis therapy and as a treatment.
Why the study?
Does intravenous NaEDTA improve supraventricular and ventricular arrhythmias?
Case Report (n=14)
Does intravenous NaEDTA improve supraventricular and ventricular arrhythmias?
This early case series describes the use of intravenous NaEDTA for treating supraventricular and ventricular arrhythmias, particularly in the context of digitalis therapy.
Should not change arrhythmia management; leaves open NaEDTA utility as a digitalis toxicity test.
The interrelated effects of digitalis and various cations on cardiac rhythmicity are the subject of much recent interest. This paper presents additional data on this subject that carry important therapeutic implications. The chelating agent, disodium ethylene diamine tetra acetate (NaEDTA), has been used intravenously in 14 instances of supraventricular and ventricular arrhythmia. Digitalis had been administered previously in 13 instances, and various degrees of digitalization were encountered. This report summarizes our experience with NaEDTA as a test of the degree of digitalis therapy and as treatment of the arrhythmias observed.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (1959) conducted a case report in Supraventricular and ventricular arrhythmia (n=14). NaEDTA (disodium ethylene diamine tetra acetate) was evaluated. Intravenous NaEDTA was administered in 14 instances of supraventricular and ventricular arrhythmia to evaluate its utility as a test of digitalis therapy and as a treatment.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: